Dr. Clay Siegall is the co-founder of Seattle Genetics. He established the company in 1998 and became CEO, President and Chairman of the Board of Directors. During his reign, Siegall enabled Seattle Genetics to build a diverse pharmaceutical line of antibody drugs for cancer therapies such as ADCETRICS. Clay Siegall is dedicated to his work. He has a passion of combating cancer challenges. He believes he can achieve his objective through his organization.
Seattle Genetics is a company that is making great strides in the medical industry. At its headquarters is a green triangular sculpture that is made of Lego bricks. The structure shows a simple model of a human antibody. Settle Genetics has specialized in the study of human antibodies for years. Since it was established in 1998, the company has manipulated, designed and packaged antibodies into multiple drugs. The antibody must connect to something else, such as therapy. It delivers a toxic substance into the cancerous cells and destroys such tissues.
Seattle Genetics has a recorded a tremendous growth over the past 5 years. Its stock has tripled since 2013, from $20 to $60 per share. Valuations show high chances of future success. Seattle`s main focus is antibody-drug conjugate (ADC), a drug that targets antigens. The drug has been used to reduce the damage that is caused by traditional methods such as radiography and chemotherapy. Siegall believes several drugs have a high potential for success. Such include Adcetris, 33A, 22ME and LIV1.
Clay Siegall is an optimistic person who believes he will succeed regardless of the political turmoil. He notes that drug production is not easy. He has to cope with various challenges. He was mentored by Art Levinson, one of Genentech founders. He believes he has to diversify his risk by producing multiple drugs.
About Clay Siegall
Dr. Clay Siegall is a scientist who focused his research on cancer therapies. He built the organization by believing in his scientific innovations, rigorous research and unique drug development practices. He has guided Seattle Genetics to acquire its leadership position in manufacturing antibody-drug conjugates (ADC) that are used in cancer therapies.
Clay has helped the organization to acquire multiple contracts for the supply of its ADC medicine. He also helped to secure several licenses for its technology. Some of the main partners include Genentech, AbbVie, Pfizer, GlaxoSmithKline. These organizations have enabled Seattle Genetics to secure over $300 million. Dr. Siegall also led several capital-raising functions that generated over $1.2 billion, through private and public financing.